A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Study finds that a significant proportion of adults prescribed GLP-1 RAs for weight management discontinue treatment within a ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to U.S. Food and Drug Administration ...

Truveta Research explored the factors associated with discontinuation and subsequent reinitiation of GLP-1 RAs among adults with overweight or obesity. "Given the huge obesity and diabetes ...

Brito, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues estimated the risk for incident thyroid cancer among adults with type 2 diabetes being treated with GLP-1 RAs vs other ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to US Food and Drug Administration ...

Websites that sell compounded GLP-1 RAs often partially inform or misinform consumers, including with respect to US FDA approval. HealthDay News — Websites that sell compounded glucagon-like peptide-1 ...